CRDF Cardiff Oncology Corp Earnings per share for the last twelve months

CRDF (Cardiff Oncology Inc.) - company brandmark

Cardiff Oncology, Inc. (CRDF) is expanding its presence in the tumor resistance segment by implementing a precision therapy ecosystem based on Onvansertib and PLK1 to create exclusive protocols. The annual EPS TTM snapshot demonstrates profit dynamics, with the metric holding around -0.54. The asset's value is based on scientific potential in the field of vital oncology, which renders the business a defensive asset against GDP fluctuations.

CRDF (Cardiff Oncology, Inc.) Net earnings per share for the last 12 months history from 07/04/2022 to 11/17/2026

Cardiff Oncology, Inc. - analytical breakdowns and key metrics (CRDF)

- current quotes and average value forecast:
Basic company analysis:Cardiff Oncology Inc. (CRDF)
Mass-produced product of Cardiff Oncology Corp

Earnings per share (EPS TTM) reflects the portion of annual net income allocated to each security, allowing for an assessment of the business's actual capitalization efficiency regardless of the total issuance volume. By analyzing the trailing specific earnings of Cardiff Oncology, Inc. (CRDF), an investor can see how support from pharma behemoths and the success of oncology drugs translate into the asset's financial stability.

Analysis of competing companies

INCY - Earnings per share for the last twelve months|HCM (HUTCHMED) - Earnings per share for the last 12 months|Nuvation Bio Inc. (NUVB) - Earnings per share for the last twelve months|Earnings per share for the last 12 months DAWN|MNPR (monopartx.com) - Net earnings per share (EPS TTM)|Net earnings per share for the last 12 months inhibrx.com (INBX)|Earnings per share for the last twelve months I-Mab (IMAB)|FENC - Net earnings per one share for the last twelve months|Earnings per share for the last twelve months Heron Therapeutics Inc HRTX|Nuvectis Pharma, Inc - Earnings per share for the last twelve months|CHRS - Earnings per share for the last twelve months|Net earnings per one share for the last twelve months Corbus Pharmaceuticals|BYSI: Net earnings per share (EPS TTM)|Net earnings per share for the trailing year BioAtla, Inc. BCAB|Net earnings per share for the last 12 months LIXT|Net earnings per one share for the last twelve months Citius Pharmaceuticals, Inc. CTXR|Net earnings per share for the last 12 months CLRB (Cellectar Biosciences)|BLRX (BioLineRx) - Earnings per share for the trailing year|Can-Fite BioPharma - Net earnings per share for the last 12 months|Earnings per share for the last four quarters APRE (Aprea)|Kazia Therapeutics Limited - Net earnings per share (EPS TTM)|Earnings per share for the trailing year SLXN (silexion.com)|NCNA: Net earnings per share (EPS TTM)|Net earnings per one share for the last twelve months chimerix.com (CMRX)|Earnings per share for the last twelve months Cyclacel|GTHX: Earnings per share for the trailing year|Net earnings per share (EPS TTM) KRON|Net earnings per share (EPS TTM) Kintara Pharma (KTRA)|Earnings per share for the last twelve months Oncternal ONCT|PRTG (Portage Biotech) - Earnings per one share for the last 12 months